Literature DB >> 33583820

Genetic variants associated with atrial fibrillationand long-term recurrence after catheter ablation for atrialfibrillation in Turkish patients.

Taner Ulus1, Muhammet Dural1, Pelin Meşe1, Furkan Yetmiş1, Kadir Uğur Mert1, Bülent Görenek1, Oğuz Çilingir2, Ebru Erzurumluoglu Gökalp2, Serap Arslan2, Sevilhan Artan2, Özlem Aykaç3, Ertuğrul Çolak4, Hikmet Yorgun5, Uğur Canpolat5, Kudret Aytemir5.   

Abstract

OBJECTIVE: Genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) are associated with atrial fibrillation (AF) and can predict AF recurrence after catheter ablation in different populations. However, there exists no such data for the Turkish population. We aimed to investigate whether 11 SNPs in the PITX2, ZFHX3, EPHX2, CAV1, TBX5, TGF-1, and SCN10A were related to AF and whether these SNPs can predict long-term atrial tachyarrhythmia (ATa) recurrence after pulmonary vein isolation (PVI) for AF in Turkish patients.
METHODS: A total of 245 consecutive patients with non-valvular AF (44.9% men, mean age: 60.2±13.2 years, 65.3% paroxysmal AF) and 50 age- and sex-matched controls were included in this analysis. The clinical features and genetic variants were compared between the 2 groups. Of the 245 patients, 128 who underwent PVI with second-generation cryoballoon were further examined for long-term recurrence after the procedure.
RESULTS: Four SNPs in PITX2 were significantly associated with AF (rs10033464_T: OR 3.29, 95%CI: 1.38-7.82, p=0.007; rs6838973_T: OR 3.06, 95% CI 1.36-6.87, p=0.007; rs3853445_C: OR 2.84, 95%CI: 1.27-6.36, p=0.011; rs17570669_T: OR 4.03, 95% CI: 1.71-9.51, p=0.001). Among these patients who underwent PVI, one locus in CAV1 (rs3807989_G: OR 4.50, 95% CI 1.04-19.31, p=0.043) and early recurrence (OR: 8.06, 95% CI: 2.12-30.55, p=0.002) predicted long-term AF recurrence after catheter ablation.
CONCLUSION: Significant associations exists between 4 SNPs in PITX2 and AF (rs10033464, rs6838973, rs3853445, and rs17570669) in Turkish patients. In addition, 1 genetic variant in CAV1 (rs3807989) and early recurrence can predict long-term ATa recurrence after catheter ablation.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33583820      PMCID: PMC8114647          DOI: 10.14744/AnatolJCardiol.2020.44082

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


  32 in total

1.  Long-term outcomes of pulmonary vein isolation using second-generation cryoballoon during atrial fibrillation ablation.

Authors:  Ugur Canpolat; Duygu Kocyigit; Muhammed Ulvi Yalcin; Cem Coteli; Yusuf Ziya Sener; Metin Oksul; Kadri Murat Gürses; Banu Evranos; Hikmet Yorgun; Kudret Aytemir
Journal:  Pacing Clin Electrophysiol       Date:  2019-05-31       Impact factor: 1.976

2.  Genetic Variants Associated With Susceptibility to Atrial Fibrillation in a Japanese Population.

Authors:  Lian Liu; Yusuke Ebana; Jun-Ichi Nitta; Yoshihide Takahashi; Shinsuke Miyazaki; Toshihiro Tanaka; Masatoshi Komura; Mitsuaki Isobe; Tetsushi Furukawa
Journal:  Can J Cardiol       Date:  2016-11-04       Impact factor: 5.223

3.  Caveolin-1 exists and may function in cardiomyocytes.

Authors:  Woo Jung Cho; Ava K Chow; Richard Schulz; Edwin E Daniel
Journal:  Can J Physiol Pharmacol       Date:  2010-01       Impact factor: 2.273

4.  Genomic variant in CAV1 increases susceptibility to coronary artery disease and myocardial infarction.

Authors:  Shanshan Chen; Xiaojing Wang; Junhan Wang; Yuanyuan Zhao; Dan Wang; Chengcheng Tan; Jingjing Fa; Rongfeng Zhang; Fan Wang; Chaoping Xu; Yufeng Huang; Sisi Li; Dan Yin; Xin Xiong; Xiuchun Li; Qiuyun Chen; Xin Tu; Yanzong Yang; Yonglong Xia; Chengqi Xu; Qing K Wang
Journal:  Atherosclerosis       Date:  2016-01-08       Impact factor: 5.162

5.  Incident atrial fibrillation among Asians, Hispanics, blacks, and whites.

Authors:  Thomas A Dewland; Jeffrey E Olgin; Eric Vittinghoff; Gregory M Marcus
Journal:  Circulation       Date:  2013-10-08       Impact factor: 29.690

Review 6.  Variant rs2200733 on chromosome 4q25 confers increased risk of atrial fibrillation: evidence from a meta-analysis.

Authors:  Sanghamitra Mohanty; Pasquale Santangeli; Rong Bai; Luigi Di Biase; Prasant Mohanty; Agnes Pump; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2012-11-06

7.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

8.  Korean Atrial Fibrillation (AF) Network: Genetic Variants for AF Do Not Predict Ablation Success.

Authors:  Eue-Keun Choi; Jae Hyung Park; Ji-Young Lee; Chung Mo Nam; Min Ki Hwang; Jae-Sun Uhm; Boyoung Joung; Young-Guk Ko; Moon-Hyoung Lee; Steven A Lubitz; Patrick T Ellinor; Hui-Nam Pak
Journal:  J Am Heart Assoc       Date:  2015-08-13       Impact factor: 5.501

9.  Cryoballoon vs. open irrigated radiofrequency ablation for paroxysmal atrial fibrillation: long-term FreezeAF outcomes.

Authors:  Armin Luik; Kevin Kunzmann; Patrick Hörmann; Kerstin Schmidt; Andrea Radzewitz; Peter Bramlage; Thomas Schenk; Gerhard Schymik; Matthias Merkel; Meinhard Kieser; Claus Schmitt
Journal:  BMC Cardiovasc Disord       Date:  2017-05-25       Impact factor: 2.298

Review 10.  Genetics of Atrial Fibrillation.

Authors:  Julien Feghaly; Patrick Zakka; Barry London; Calum A MacRae; Marwan M Refaat
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.